Click here to view with images.
To ensure delivery to your inbox, please add alex.fernandez@nmrk.com to your address book.
 
WEEKLY RATE INFORMATION
Market Index
¹ Excludes dividends
Sources: Yahoo! Finance, U.S. Dept of the Treasury, U.S. EIA, Barchart (SWAADY10.RT), Bloomberg, World Gold Council
¹ Excludes dividends
Sources: Yahoo! Finance, U.S. Dept of the Treasury, U.S. EIA, Barchart (SWAADY10.RT), Bloomberg, World Gold Council
Top U.S. Senate Democrat vows vote on Biden's $1.75 trln bill despite Manchin's rejection

WASHINGTON, Dec 20 (Reuters) - The U.S. Senate will vote early next year on President Joe Biden's sweeping $1.75 trillion policy bill as well as on voting rights, the chamber's top Democrat said on Monday, despite conservative Democratic Senator Joe Manchin's opposition.

Senate Majority Leader Chuck Schumer unveiled plans for both votes on Monday, the day after Manchin -- who has stood as a roadblock to many Biden policies in the evenly divided chamber -- said in a television interview that he would not vote for the "Build Back Better" bill, dealing it a potentially fatal blow.

Covid: Christmas travel will fuel spread of Omicron, US expert warns

Christmas travel will increase the spread of the Omicron Covid-19 variant, even among the fully vaccinated, the top US infectious disease expert says.

"There's no doubt about this, [Omicron] has an extraordinary capability of spreading," Dr Anthony Fauci told NBC's Meet the Press programme on Sunday.

Dr Fauci, who advises the US government on the pandemic, said the variant was now "raging through the world".

Moderna’s Third Dose Boosts Antibodies Against Omicron

A third dose of Moderna Inc.’s Covid-19 vaccine increased antibody levels against the omicron variant, results the company described as reassuring while it works on a shot tailored to the new strain. 

A 50 microgram booster dose produced a 37-fold increase in neutralizing antibodies, the company said in a statement Monday. That is the same dose as the currently authorized Moderna booster, which is half the dose used for primary immunization.

contact
Aaron Swerdlin
Vice Chairman
aaron.swerdlin@nmrk.com
Kenneth Cox
Executive Managing Director
kenneth.cox@nmrk.com
contact
Taucha Hogue
Managing Director
taucha.hogue@nmrk.com
1700 Post Oak Blvd, 2 BLVD Place Suite 250
Houston, TX 77056
t 713-626-8888
nmrkstorage.com
InstagramFacebookLinkedInTwitter
Unsubscribe
1700 Post Oak Blvd, 2 BLVD Place Suite 250, Houston, TX 77056 t 713-626-8888
 
All information contained in this publication is derived from sources that are deemed to be reliable. However, Newmark has not verified any such information, and the same constitutes the statements and representations only of the source thereof, and not of Newmark. Any recipient of this publication should independently verify such information and all other information that may be material to any decision that recipient may make in response to this publication, and should consult with professionals of the recipient's choice with regard to all aspects of that decision, including its legal, financial, and tax aspects and implications. Any recipient of this publication may not, without the prior written approval of Newmark, distribute, disseminate, publish, transmit, copy, broadcast, upload, download, or in any other way reproduce this publication or any of the information it contains. This document is intended for informational purposes only and none of the content is intended to advise or otherwise recommend a specific strategy. It is not to be relied upon in any way to predict market movement, investment in securities, transactions, investment strategies or any other matter.

©2024 Newmark. All Rights Reserved.